Hikma Pharmaceuticals (LON:HIK) Trading Down 13.3% on Analyst Downgrade

Shares of Hikma Pharmaceuticals PLC (LON:HIK) fell 13.3% during mid-day trading on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,531 and last traded at GBX 1,536. 5,610,586 shares changed hands during trading, an increase of 328% from the average session volume of 1,312,058 shares. The stock had previously closed at GBX 1,771.

A number of other equities research analysts also recently commented on HIK. Deutsche Bank Aktiengesellschaft reduced their target price on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Peel Hunt reissued a “buy” rating and set a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research report on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals has a consensus rating of “Buy” and an average target price of GBX 2,416.

Insider Activity

In other Hikma Pharmaceuticals news, insider Laura Balan Balan purchased 3,500 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were bought at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 315,000 shares of Hikma Pharmaceuticals stock in a transaction dated Thursday, November 6th. The shares were acquired at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150. Over the last ninety days, insiders acquired 332,500 shares of company stock valued at $533,130,500. 17.77% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Stock Up 3.9%

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company has a market cap of £3.50 billion, a PE ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The business’s 50 day moving average is GBX 1,730.88 and its 200-day moving average is GBX 1,893.97.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.